Trulicity

Țară: Uniunea Europeană

Limbă: engleză

Sursă: EMA (European Medicines Agency)

Cumpara asta acum

Prospect Prospect (PIL)
16-03-2023

Ingredient activ:

dulaglutide

Disponibil de la:

Eli Lilly Nederland B.V.

Codul ATC:

A10BJ05

INN (nume internaţional):

dulaglutide

Grupul Terapeutică:

Drugs used in diabetes, Blood glucose lowering drugs, excl. insulins

Zonă Terapeutică:

Diabetes Mellitus, Type 2

Indicații terapeutice:

Trulicity is indicated for the treatment of patients 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.

Rezumat produs:

Revision: 17

Statutul autorizaţiei:

Authorised

Data de autorizare:

2014-11-21

Prospect

                                72
B. PACKAGE LEAFLET
73
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
TRULICITY 0.75 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
TRULICITY 1.5 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
TRULICITY 3 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
TRULICITY 4.5 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
dulaglutide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Trulicity is and what it is used for
2.
What you need to know before you use Trulicity
3.
How to use Trulicity
4.
Possible side effects
5.
How to store Trulicity
6.
Contents of the pack and other information
1.
WHAT TRULICITY IS AND WHAT IT IS USED FOR
Trulicity contains an active substance called dulaglutide and is used
to lower blood sugar (glucose) in
adults and children aged 10 years and above, with type 2 diabetes
mellitus and can help prevent heart
disease.
Type 2 diabetes is a condition in which your body does not make enough
insulin, and the insulin that
your body produces does not work as well as it should.
When this happens, sugar (glucose) builds up in the blood.
Trulicity is used:
-
on its own if your blood sugar is not properly controlled by diet and
exercise alone, and you
can’t take metformin (another diabetes medicine).
-
or with other medicines for diabetes when they are not enough to
control your blood sugar
levels. These other medicines may be medicines taken by mouth and/or
insulin given by
injection.
It is important to continue to follow the advice on diet and exercise
given to you by your doctor,
pharmac
                                
                                Citiți documentul complet
                                
                            

Caracteristicilor produsului

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Trulicity 0.75 mg solution for injection in pre-filled pen
Trulicity 1.5 mg solution for injection in pre-filled pen
Trulicity 3 mg solution for injection in pre-filled pen
Trulicity 4.5 mg solution for injection in pre-filled pen
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Trulicity 0.75 mg solution for injection in pre-filled pen
Each pre-filled pen contains 0.75 mg of dulaglutide* in 0.5 ml
solution.
Trulicity 1.5 mg solution for injection in pre-filled pen
Each pre-filled pen contains 1.5 mg of dulaglutide* in 0.5 ml
solution.
Trulicity 3 mg solution for injection in pre-filled pen
Each pre-filled pen contains 3 mg of dulaglutide* in 0.5 ml solution.
Trulicity 4.5 mg solution for injection in pre-filled pen
Each pre-filled pen contains 4.5 mg of dulaglutide* in 0.5 ml
solution.
*produced in CHO cells by recombinant DNA technology.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection.
Clear, colourless solution.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Type 2 Diabetes Mellitus
Trulicity is indicated for the treatment of patients 10 years and
above with insufficiently controlled
type 2 diabetes mellitus as an adjunct to diet and exercise
•
as monotherapy when metformin is considered inappropriate due to
intolerance or
contraindications
•
in addition to other medicinal products for the treatment of diabetes.
For study results with respect to combinations, effects on glycaemic
control and cardiovascular events,
and the populations studied, see sections 4.4, 4.5 and 5.1.
3
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
_ _
Posology
_Adults _
_ _
_Monotherapy _
The recommended dose is 0.75 mg once weekly.
_Add-on therapy_
The recommended dose is 1.5 mg once weekly.
If needed,
•
the 1.5 mg dose can be increased after at least 4 weeks to 3 mg once
weekly.
•
the 3 mg dose can be increased after at least 4 weeks to 4.5 mg once
weekly.
The maximum dose is 4.5 mg once weekly.
_Paediatri
                                
                                Citiți documentul complet
                                
                            

Documente în alte limbi

Prospect Prospect bulgară 16-03-2023
Caracteristicilor produsului Caracteristicilor produsului bulgară 16-03-2023
Raport public de evaluare Raport public de evaluare bulgară 16-03-2023
Prospect Prospect spaniolă 16-03-2023
Caracteristicilor produsului Caracteristicilor produsului spaniolă 16-03-2023
Raport public de evaluare Raport public de evaluare spaniolă 16-03-2023
Prospect Prospect cehă 16-03-2023
Caracteristicilor produsului Caracteristicilor produsului cehă 16-03-2023
Raport public de evaluare Raport public de evaluare cehă 16-03-2023
Prospect Prospect daneză 16-03-2023
Caracteristicilor produsului Caracteristicilor produsului daneză 16-03-2023
Raport public de evaluare Raport public de evaluare daneză 16-03-2023
Prospect Prospect germană 16-03-2023
Caracteristicilor produsului Caracteristicilor produsului germană 16-03-2023
Raport public de evaluare Raport public de evaluare germană 16-03-2023
Prospect Prospect estoniană 16-03-2023
Caracteristicilor produsului Caracteristicilor produsului estoniană 16-03-2023
Raport public de evaluare Raport public de evaluare estoniană 16-03-2023
Prospect Prospect greacă 16-03-2023
Caracteristicilor produsului Caracteristicilor produsului greacă 16-03-2023
Raport public de evaluare Raport public de evaluare greacă 16-03-2023
Prospect Prospect franceză 16-03-2023
Caracteristicilor produsului Caracteristicilor produsului franceză 16-03-2023
Raport public de evaluare Raport public de evaluare franceză 16-03-2023
Prospect Prospect italiană 16-03-2023
Caracteristicilor produsului Caracteristicilor produsului italiană 16-03-2023
Raport public de evaluare Raport public de evaluare italiană 16-03-2023
Prospect Prospect letonă 16-03-2023
Caracteristicilor produsului Caracteristicilor produsului letonă 16-03-2023
Raport public de evaluare Raport public de evaluare letonă 16-03-2023
Prospect Prospect lituaniană 16-03-2023
Caracteristicilor produsului Caracteristicilor produsului lituaniană 16-03-2023
Raport public de evaluare Raport public de evaluare lituaniană 16-03-2023
Prospect Prospect maghiară 16-03-2023
Caracteristicilor produsului Caracteristicilor produsului maghiară 16-03-2023
Raport public de evaluare Raport public de evaluare maghiară 16-03-2023
Prospect Prospect malteză 16-03-2023
Caracteristicilor produsului Caracteristicilor produsului malteză 16-03-2023
Raport public de evaluare Raport public de evaluare malteză 16-03-2023
Prospect Prospect olandeză 16-03-2023
Caracteristicilor produsului Caracteristicilor produsului olandeză 16-03-2023
Raport public de evaluare Raport public de evaluare olandeză 16-03-2023
Prospect Prospect poloneză 16-03-2023
Caracteristicilor produsului Caracteristicilor produsului poloneză 16-03-2023
Raport public de evaluare Raport public de evaluare poloneză 16-03-2023
Prospect Prospect portugheză 16-03-2023
Caracteristicilor produsului Caracteristicilor produsului portugheză 16-03-2023
Raport public de evaluare Raport public de evaluare portugheză 16-03-2023
Prospect Prospect română 16-03-2023
Caracteristicilor produsului Caracteristicilor produsului română 16-03-2023
Raport public de evaluare Raport public de evaluare română 16-03-2023
Prospect Prospect slovacă 16-03-2023
Caracteristicilor produsului Caracteristicilor produsului slovacă 16-03-2023
Raport public de evaluare Raport public de evaluare slovacă 16-03-2023
Prospect Prospect slovenă 16-03-2023
Caracteristicilor produsului Caracteristicilor produsului slovenă 16-03-2023
Raport public de evaluare Raport public de evaluare slovenă 16-03-2023
Prospect Prospect finlandeză 16-03-2023
Caracteristicilor produsului Caracteristicilor produsului finlandeză 16-03-2023
Raport public de evaluare Raport public de evaluare finlandeză 16-03-2023
Prospect Prospect suedeză 16-03-2023
Caracteristicilor produsului Caracteristicilor produsului suedeză 16-03-2023
Raport public de evaluare Raport public de evaluare suedeză 16-03-2023
Prospect Prospect norvegiană 16-03-2023
Caracteristicilor produsului Caracteristicilor produsului norvegiană 16-03-2023
Prospect Prospect islandeză 16-03-2023
Caracteristicilor produsului Caracteristicilor produsului islandeză 16-03-2023
Prospect Prospect croată 16-03-2023
Caracteristicilor produsului Caracteristicilor produsului croată 16-03-2023
Raport public de evaluare Raport public de evaluare croată 16-03-2023

Căutați alerte legate de acest produs

Vizualizați istoricul documentelor